At­las Ven­ture, one of biotech’s go-to VC firms, is eye­ing a $450 mil­lion 14th fund, part­ner Bruce Booth said in its ...

Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...

San Diego biotech Aven­zo Ther­a­peu­tics has in-li­censed an­oth­er as­set, this time se­cur­ing the glob­al ex-Chi­na ...

Cy­bin said its psilocin ana­log has the po­ten­tial to wipe out symp­toms in most pa­tients with a se­ri­ous form of ...

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...

Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...

AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...

Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...